Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.270
+0.020 (0.47%)
Aug 17, 2026, 12:39 PM EDT - Market open
Aquestive Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 98.49 | 121.17 | 71.55 | 23.87 | 27.27 | 28.02 |
Cash & Short-Term Investments | 98.49 | 121.17 | 71.55 | 23.87 | 27.27 | 28.02 |
Cash Growth | 62.70% | 69.36% | 199.71% | -12.47% | -2.68% | -11.89% |
Accounts Receivable | 9.33 | 17.76 | 7.34 | 8.47 | 4.7 | 12.12 |
Receivables | 9.33 | 17.76 | 7.34 | 8.47 | 4.7 | 12.12 |
Inventory | 7.37 | 6.17 | 6.04 | 6.77 | 5.78 | 4.04 |
Prepaid Expenses | 3.31 | 4.17 | 3.29 | 1.85 | 2.13 | 3.08 |
Total Current Assets | 118.49 | 149.27 | 88.22 | 40.97 | 39.89 | 47.26 |
Property, Plant & Equipment | 11.91 | 8.51 | 8.98 | 9.74 | 9.3 | 7.78 |
Other Intangible Assets | - | - | - | 1.28 | 1.44 | 0.05 |
Other Long-Term Assets | 1.7 | 2.64 | 4.22 | 5.44 | 6.45 | 6.9 |
Total Assets | 132.1 | 160.43 | 101.42 | 57.42 | 57.07 | 61.99 |
Accounts Payable | 8.97 | 29.86 | 10.29 | 8.93 | 9.95 | 8.31 |
Accrued Expenses | 4.57 | 5.03 | 5.99 | 6.5 | 7.97 | 8.74 |
Current Portion of Long-Term Debt | 0.03 | 9.99 | 0.03 | 0.02 | 18.7 | 2.03 |
Current Portion of Leases | 0.82 | 0.63 | 0.51 | 0.39 | 0.26 | 0.9 |
Current Unearned Revenue | 2.09 | 2.09 | 2.05 | 2.47 | 2.66 | 1.99 |
Total Current Liabilities | 16.48 | 47.61 | 18.87 | 18.31 | 39.53 | 21.96 |
Long-Term Debt | 50.56 | 27.41 | 32.35 | 27.34 | 33.45 | 51.55 |
Long-Term Leases | 7.62 | 4.45 | 5.11 | 5.57 | 5.09 | 1.95 |
Long-Term Unearned Revenue | 80.01 | 81.41 | 82.72 | 95.91 | 95.53 | 66.18 |
Other Long-Term Liabilities | 34.02 | 33.21 | 22.52 | 16.78 | 2.03 | 2.49 |
Total Liabilities | 188.69 | 194.09 | 161.58 | 163.91 | 175.62 | 144.13 |
Common Stock | 0.13 | 0.12 | 0.09 | 0.07 | 0.06 | 0.04 |
Additional Paid-In Capital | 421.21 | 413.21 | 302.97 | 212.52 | 192.6 | 174.62 |
Retained Earnings | -477.92 | -447 | -363.21 | -319.08 | -311.21 | -256.8 |
Total Common Equity | -56.59 | -33.66 | -60.16 | -106.49 | -118.55 | -82.13 |
Shareholders' Equity | -56.59 | -33.66 | -60.16 | -106.49 | -118.55 | -82.13 |
Total Liabilities & Equity | 132.1 | 160.43 | 101.42 | 57.42 | 57.07 | 61.99 |
Total Debt | 59.03 | 42.48 | 38 | 33.32 | 57.49 | 56.42 |
Net Cash (Debt) | 39.46 | 78.69 | 33.54 | -9.45 | -30.22 | -28.4 |
Net Cash Growth | 94.59% | 134.59% | - | - | - | - |
Net Cash Per Share | 0.33 | 0.74 | 0.39 | -0.15 | -0.62 | -0.75 |
Filing Date Shares Outstanding | 125.51 | 122.05 | 98.87 | 73.3 | 55.87 | 41.47 |
Total Common Shares Outstanding | 125.51 | 122.04 | 91.41 | 68.53 | 54.83 | 41.23 |
Working Capital | 102.02 | 101.66 | 69.36 | 22.66 | 0.36 | 25.3 |
Book Value Per Share | -0.45 | -0.28 | -0.66 | -1.55 | -2.16 | -1.99 |
Tangible Book Value | -56.59 | -33.66 | -60.16 | -107.77 | -119.99 | -82.19 |
Tangible Book Value Per Share | -0.45 | -0.28 | -0.66 | -1.57 | -2.19 | -1.99 |
Machinery | 26.43 | 24.29 | 23.77 | 23.64 | 23.21 | 22.49 |
Construction In Progress | 0.38 | 2.2 | 2.11 | 2.03 | 1.47 | 1.16 |
Leasehold Improvements | 21.42 | 21.42 | 21.42 | 21.39 | 21.38 | 21.27 |